We have shown that failure to degrade SHARP1 impairs triple-negative breast cancer suggesting that pharmacological strategies aimed at blocking the interaction of SHARP1 with βTrCP would represent a potential anticancer therapeutic approach. The gene discussed is BTRC; the disease is triple-negative breast carcinoma.